





OVERVIEW

Recorded live on May 14-15, 2021, this on demand program features updated information on lymphoma biology, diagnosis, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphoma subtypes.

Highlights of this on demand program include:

- A focus on the recent treatment options developed for patients with relapsed or refractory disease as well as discussions on how to best approach patients' situation.
- A special session on recent advances in the biology of lymphoma and how this will translate to innovative therapeutic interventions.
- Discussions on diagnostic and management cases, and how to incorporate biomarkers and imaging into clinical practice and clinical trials.

The target audience for this activity includes medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.

MSK COURSE DIRECTOR



Gilles Salles, MD, PhD Chief, Lymphoma Service

MSK PLANNING COMMITTEE



Ahmet Dogan, MD, PhD
Chief, Hematopathology Service
Departments of Pathology and
Laboratory Medicine



Steven Horwitz, MD Medical Oncologist



Andrew Intlekofer, MDAssistant Member,
Human Oncology & Pathogenesis Program



Ariela Noy, MD Medical Oncologist



Hans-Guido Wendel, MD Member/Professor, Cancer Biology & Genetics Program



Joachim Yahalom, MD Radiation Oncologist



Andrew D. Zelenetz, MD, PhDMedical Director, Quality Informatics

FACULTY

KEYNOTE SPEAKERS



Michel Sadelain, MD, PhD
Director, Center for Cell Engineering;
Stephen and Barbara Friedman Chair
Memorial Sloan Kettering Cancer Center
New York, NY



David Weinstock, MDLavine Family Chair for
Preventative Cancer Therapies
Dana-Farber Cancer Institute
Boston, MA

INVITED COURSE FACULTY

Philippe Armand, MD, PhD

Chief, Division of Lymphoma Dana-Farber Cancer Institute Boston, MA

Martin Dreyling, MD, PhD

Professor of Medicine University of Munich Munich, Germany

Gregor S. Nowakowski, MD

Consultant, Division of Hematology Department of Internal Medicine Mayo Clinic Rochester, Minnesota

Simon Rule, MD, PhD

Professor in Haematology Plymouth University Medical School Plymouth, UK

MSK COURSE FACULTY

Caleb Ho. MD

Pathologist

Anita Kumar, MD

Regional Care Network Medical Site Director, MSK Basking Ridge

Alison Moskowitz, MD

Clinical Director, Lymphoma Inpatient Unit

M. Lia Palomba, MD

Medical Oncologist

Craig Sauter, MD

Clinical Director, Adult Bone Marrow Transplant Service

Heiko Schoder, MD, MBA

Chief, Molecular Imaging and Therapy Service

Hodgkin Lymphoma (HL)

CHAIR: Steven Horwitz, MD

15 MIN. PET-CT in HL: Recent Insights

Heiko Schoder, MD, MBA

15 MIN. Can ASCT be Avoided in Relapsed HL

Alison Moskowitz, MD

15 MIN. ASCT & Cellular Therapies in HL

Philippe Armand, MD, PhD

10 MIN. Panel Discussion: Q&A

Keynote Presentation

MODERATOR: Steven Horwitz, MD

35 MIN. New Vulnerabilities in T-cell Lymphomas

David Weinstock, MD

Diffuse Large B-cell Lymphoma (DLBCL)

CHAIR: Ariela Noy, MD

10 MIN. DLBCL Pathology: New Insights

Ahmet Dogan, MD, PhD

20 MIN. Positioning CAR-T in Relapsed / Refractory DLBCL

Craig Sauter, MD

20 MIN. Effective and Off the Shelf -

New Agents in Relapsed and Refractory DLBCL

Gregor Nowakowski, MD

15 MIN. Panel Discussion: Q&A

Mantle Cell Lymphoma

CHAIR: Anita Kumar, MD

10 MIN. MCL Pathology: New Insights

Caleb Ho, MD

15 MIN. Targeted Therapies in MCL

Simon Rule, MD, PhD

15 MIN. CAR-T in R/R MCL

M. Lia Palomba, MD

15 MIN. Panel Discussion: Q&A

Follicular Lymphoma (FL)

CHAIR: Andrew D. Zelenetz, MD, PhD

15 MIN. Less is More: New RT Paradigm for Indolent Lymphomas

Joachim Yahalom, MD

15 MIN. Managing Early Relapses in FL: The Role of Chemotherapy

Martin Drevling, MD, PhD

15 MIN. Management of Early Relapses: New Agents

Gilles Salles, MD, PhD

15 MIN. Panel Discussion: Q&A

Keynote Presentation

MODERATOR: Gilles Salles, MD, PhD

35 MIN. Lessons from CD19 CAR Therapy

Michel Sadelain, MD, PhD

REGISTER ONLINE:

mskcc.org/lymphomasymposiumonline

On Demand Registration Fees

Physicians (MDs, PhDs and DOs): \$200

Nurses, PAs and Other Healthcare Professionals: \$50

Residents and Fellows: \$50

Industry Professionals: \$500

By registering for this on demand program, you will receive access to videos from the 5th Annual MSK Symposium on Lymphoma, originally recorded on May 14-15, 2021. This on demand program will be available for purchase until November 30, 2021.Access to the videos and claiming credit will be available until February 28, 2021.

Registration Discounts/Promotions

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners.
- MSK employee registration is complimentary; however, you must complete course registration in order to attend this course.

For additional details on registration, please visit the course website:

mskcc.org/lymphomasymposiumonline

ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **5.00** *AMA PRA Category 1 Credits* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.



